Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
Zacks139d agobearish
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%Zacks142d agobearish
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesUltragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks147d agobearish
Pacira (PCRX) Q1 Earnings Miss EstimatesPacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?